A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain

Inclusion Criteria: * Men or women of at least 18 years of age * Body weight of more than 40 kg and less than 120 kg with a BMI between 19-31 kg/m2 inclusive * Diagnosed with Peripheral Neuropathic Pain (PNP) since at least 6 months * Being affiliated with the national welfare system * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures * Have given written informed consent approved by the relevant Ethics Committee (EC) governing the study site PNP disease diagnosis inclusion criteria: * Patient with chronic PNP supported by a distinct neuroanatomical plausible distribution with sensory signs and symptoms, and consecutive to one of the following causes: a traumatic event, a surgical procedure (excluding limb amputation), radiculopathy, post-herpetic or post-zooster neuralgia, diabetic polyneuropathy or post-anticancer chemotherapy. Diagnosis will have to be confirmed by the DN4 questionnaire at the screening visit (pain is considered as neuropathic if DN4 score ≥ 4) * Pain present since at least 6 months * Patients will be required to have a score between 4 and 8 inclusive on the mean Average Pain Score (APS) Numeric Rating Scale (NRS) during the baseline period preceding randomization (data collected in patient diary) and to have completed at least 4 days of pain assessment Exclusion Criteria: * Pregnant, breastfeeding, or willing to be pregnant within 2 months * With a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study * Uncontrolled epilepsy * Any current primary psychiatric condition, including major depression or major personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); personality disorders and mental retardation) * Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine) * Acute disease state within 7 days before Visit 2 * Any other relevant medical disorder likely to interfere with the trial or represent a risk for the patient * Any close relationship with the Investigators or the Sponsor (i.e. belonging to immediate family or subordination link) * Patient under legal protectio…